Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 15:36

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 14:50

Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 13:56

Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Abbreviations used in EMA scientific committees and Coordination Group for Mutual Recognition and Decentralised Procedures (CMD) documents, and in relation to EMA’s regulatory activities

Submitted by Anonymous (not verified) on 3 July 2026 - 12:36

Abbreviations used in EMA scientific committees and Coordination Group for Mutual Recognition and Decentralised Procedures (CMD) documents, and in relation to EMA’s regulatory activities

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More